Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EPS (Basic) (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EPS (Basic) for 4 consecutive years, with -$7.35 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) fell 4493.75% to -$7.35 in Q3 2025 year-over-year; TTM through Sep 2025 was $7.92, a 1077.78% increase, with the full-year FY2024 number at -$0.75, up 17.58% from a year prior.
  • EPS (Basic) was -$7.35 for Q3 2025 at bioAffinity Technologies, down from -$0.04 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $15.47 in Q4 2024 to a low of -$7.35 in Q3 2025.
  • A 4-year average of $0.31 and a median of -$0.19 in 2024 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): skyrocketed 6050.0% in 2024, then crashed 4493.75% in 2025.
  • bioAffinity Technologies' EPS (Basic) stood at -$0.06 in 2022, then crashed by 333.33% to -$0.26 in 2023, then surged by 6050.0% to $15.47 in 2024, then tumbled by 147.51% to -$7.35 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EPS (Basic) are -$7.35 (Q3 2025), -$0.04 (Q2 2025), and -$0.16 (Q1 2025).